Impact of quadruplet induction therapy on stem cell mobilization yields in newly diagnosed multiple myeloma

This retrospective study of 104 newly diagnosed multiple myeloma patients compared stem cell mobilization yields in those receiving daratumumab-containing quadruplet induction vs. a traditional three-drug induction. There were no significant differences in achieving the required CD34+ cell yield after the first mobilization attempt. However, the daratumumab group experienced a statistically significant longer duration of apheresis collection. The findings reinforce incorporating granulocyte-colony stimulating factors and plerixafor upfront into mobilization practices.